Hikal Ltd reported a consolidated net loss of ₹23 crore for the quarter ended June 30, 2025, compared to a net profit of ₹5 crore in the corresponding quarter of the previous fiscal year. Revenue from operations decreased by 6.5% year-on-year to ₹380 crore.
| Metric | Q1 FY26 | Q1 FY25 | YoY Change | Q4 FY25 | QoQ Change |
|---|---|---|---|---|---|
| Net Profit | -23 | 5 | -537.4% | 50 | -145.2% |
| Revenue | 380 | 407 | -6.5% | 552 | -31.1% |
| EBITDA | 25 | 58 | -57.4% | 124 | -80.0% |
| EBITDA Margin | 6.5% | 14.3% | 22.4% |
Financial Performance:
The company's EBITDA stood at ₹25 crore, a decrease of 57.4% compared to ₹58 crore in Q1 FY25. The EBITDA margin was 6.5% as against 14.3% in the corresponding quarter of the previous year.
Segmental Performance:
The pharmaceuticals segment delivered revenue of ₹203 crore. The crop protection business reported revenue of ₹178 crore for Q1 FY26.
Other Updates:
The company received an Official Action Indicated (OAI) communication from the US FDA in May 2025, which led to a temporary deferment of offtake in the pharmaceutical division. GMP audits at the Bangalore API facility by ANVISA, Brazil and PMDA Japan were successfully concluded.
Despite the challenging start to the year in Q1, the company remains confident of delivering on its guidance for FY26 and expects a more meaningful recovery in Q3 and Q4 FY26.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
